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A study on molecular characterization of macrolide resistance
mechanism among isolates of Streptococcus pneumoniae from
the southern Marmara region of Turkey, as well as resistance to
macrolides and penicillin in these isolates
Cüneyt ÖZAKIN1, Hicran GÜLER2, Emel GÜRCÜOĞLU3, Saliha BAKIR ÖZBEY4, Esra KAZAK1,
Ayşe Melda SINIRTAŞ1

Aim: To determine the distribution of macrolide resistance genes as well as resistance rates in isolated Streptococcus
pneumoniae strains from the southern Marmara region of Turkey.
Materials and methods: Antimicrobial resistance rates and MIC values were determined by the E-test method in 300
Streptococcus pneumoniae isolates that were isolated from clinical samples. Resistance genes were determined by the
polymerase chain reaction (PCR) method in erythromycin-resistant strains.
Results: It was found that 11.4% of Streptococcus pneumoniae isolates were resistant to macrolides. The penicillin MIC
value was ≥0.12 μg/mL in 23% of the strains and 2 μg/mL in 2% of the strains. The erm(B) genotype was observed
in 58.8% of all macrolide-resistant strains, 38.2% were of the mef(A) genotype, and 3% were a combination of both
genotypes.
Conclusion: Based on the data from this study, it was concluded that the local resistance to antibiotics is not as high as
that observed in other countries, and the erm(B) genotype was dominant in macrolide-resistant strains. Therefore, it is
suggested that macrolide-group antibiotics still be included in treatment protocols.
Key words: mef(A), erm(B), PCR, S. pneumoniae

Türkiye’nin Güney Marmara Bölgesi’nden izole edilen Streptococcus pneumoniae
suşlarında makrolid ve penisilin direnci ve makrolid direncinin moleküler özelliği
Amaç: Son yıllarda Streptococcus pneumoniae suşlarında makrolid ve diğer antibiyotiklere giderek artan bir direnç oranı
mevcuttur. Bu çalışmada Türkiye’de Güney Marmara Bölgesi’nden izole edilen S. pneumoniae suşlarında penisilin ve
makrolidler için minimum inhibitör konsantrasyonlarının ve makrolid direnç mekanizmasının genetik dağılımının
tespit edilmesi amaçlanmıştır.
Yöntem ve gereç: Çalışmada klinik örneklerden izole edilen 300 adet S. pneumoniae izolatında E test yöntemi ile
antimikrobiyal direnç oranları ve MIK değerleri ve eritromisine dirençli izolatlarda ise PCR yöntemiyle direnç genleri
tespit edildi.
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Bulgular: Çalışmada makrolid direnci % 11,4 oranında bulundu. Penisilin MIC değeri 0,12 μg/mL ve üzeri olan suşlar %
23 oranında, penisilin MIC değeri 2 μg/mL olan suşlar % 2 oranında bulundu. Makrolid dirençli izolatların % 58,8’inde
erm(B) genotipi, % 38,2’sinde mef(A) genotipi, ve % 3’ünde her iki direnç genotipi birden tespit edildi.
Sonuç: Bölgemizde izole edilen suşlarda antibiyotik direncinin yüksek olmadığı ve makrolid direnci olan suşlarda
erm(B) tipi direnç geninin hakim olduğu görüldü. Bölgemizde direnç oranlarının yüksek olmaması nedeniyle tedavi
protokolünde makrolid grubu antibiyotikler kullanılabilir.
Anahtar sözcükler: mef(A), erm(B), PCR, S. pneumoniae

Introduction
Streptococcus pneumoniae is the major bacterial
pathogen in community-acquired respiratory tract
infections and meningitis, both in prevalence and
in its ability to cause systemic infection with a high
level of morbidity and mortality (1-3). Macrolide
antibiotics exhibit strong antimicrobial activity
against streptococci and atypical respiratory
pathogens. Therefore, they are among the drugs that
can be used for chemotherapy of infections caused by
Streptococcus pneumoniae (1,2,4).
Macrolides and beta-lactams are commonly used
for the treatment of pneumococcal infections (1-4).
Since macrolides are largely prescribed for the empiric
chemotherapy of community-acquired respiratory
tract infections and may be useful in cases of intolerance
to β-lactams as well as pneumococcal resistance to
other antimicrobial agents, the macrolide resistance
of this organism has increased rapidly worldwide (15). Macrolide resistance in pneumococci has been
detected at variable rates in different epidemiological
studies, and increasing resistance has been reported
by several investigators (1,2,4).
In S. pneumoniae, macrolide resistance can be
mediated by 2 mechanisms: ribosomal modification
(6) or active drug efflux (7). Both resistance effectors
are encoded by acquired determinants: the erm(B)
gene encoding the ribosome-modifying enzyme and
the mef(A) gene for the efflux system (6,7). The gene
erm(B), which causes the modification of a specific
adenine residue on the 23S rRNA, is dimethylated by
rRNA methylases (6). The isolates with the erm(B)
gene show high-level resistance to macrolides,
lincosamides, and streptogramin B (MLSB-type
resistance pattern), whereas the isolates carrying
the mef(A) gene only express resistance to 14- and
15-membered ring macrolides (M-type pattern
resistance) by removing them from the cell (7).
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Macrolides are efficient at high doses in mef(A)-type
resistant strains (3,4,8). In S. pneumoniae isolates,
rates of resistance and genotypic distribution of
resistance show geographic differences (9-12).
As the data related to the genotypic distribution
and epidemiology of resistance in pneumococci
in Turkey are limited, we aimed to determine the
genotype of erythromycin-resistant S. pneumoniae
isolates by the polymerase chain reaction (PCR)
method and to define the minimum inhibitory
concentration (MIC) values of macrolides and
penicillin by the E-test method in S. pneumoniae
isolates isolated from the southern Marmara region.
Materials and methods
Included in the study were 300 S. pneumoniae
isolates isolated from culture samples taken from
patients who were residents of the southern
Marmara region of Turkey. Samples were collected
in the bacteriology laboratory of the Microbiology
and Infectious Diseases Department at the Uludağ
University Faculty of Medicine over a 7-year period
(1999 to 2005). Repeated isolates from the same
individual were not included. Of the 300 samples,
73 were taken from sputum; 66 from endotracheal
aspirates; 65 from blood; 19 from bronchoalveolar
lavage; 18 from middle-ear aspirates; 10 from
cerebrospinal fluid; 7 each from conjunctivas, acid
fluid, and pleura fluid; 5 from wounds; 16 from
nasopharyngeal aspirates; 2 each from joint fluids
and vitreous; and 1 each from isolated operation
material taken from cistern aspiration fluid and an
abscess. The identification of isolates was performed
according to standard procedures (13). All strains
were stored at –80 °C in skim milk with glycerin at
a volume of 500 μL in sterile microtubes (Cryobank
Mixed, Mast Group Ltd., Merseyside, UK), applying
1 colony passage routinely.
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The isolates that were used in this study were
vitalized by performing 1 colony passage to Columbia
agar with 5% sheep blood from storage microtubes.
After the confirmation of identification of the vitalized
isolates, in vitro susceptibility to erythromycin,
clarithromycin, azithromycin, and penicillin were
examined by E-test (AB Biodisk, Solna, Sweden) on
Mueller-Hinton agar supplemented with 5% sheep
blood. Isolates were incubated with 5% CO2 at 35 ± 2
°C for 20-24 h before reading the MICs (14).
S. pneumoniae ATCC 49619 was used as a quality
control organism for susceptibility tests.
Of the 300 pneumococcal isolates, 34 (11.4 %)
were found to be resistant to erythromycin (≥0.5
μg/mL) as a result of the E-test and were further
investigated for macrolide resistance mechanisms.
For PCR, all strains kept in incubation in Columbia
agar with 5% sheep blood for a period of 18-24 h
were used. From each isolate, 5-6 colonies were
taken and suspended in a microcentrifuge tube
containing 500 μL of RNAse- and DNAse-free
distilled water, and then suspensions were frozen
and kept at –80 °C until studied. The samples that
dissolved thoroughly were boiled at 99 °C for 10
min in a thermocycler (T3 thermocycler, Biometra,
Germany). After centrifugation for 3 min at 11,000
× g in a refrigerated centrifuge (HERMLE Z233 MK2, ALYS Labware, Lausanne, Switzerland), 10 μL of
the supernatant was used in the PCR studies as a
DNA source. The amplification was performed in a
T3 thermocycler (Biometra). The denaturation phase
of the amplification was done at 94 °C for 15 s, the
annealing phase at 52 °C for 15 s, the extension phase
at 72 °C for 15 s (37 cycles), and the postextension
phase at 72 °C for 7 min (15-17). PCR was carried
out with primers erm(B) 1, (5’-GAA AAG GTA CTC
AAC CAA ATA-3’); erm(B) 2, (5’-AGT AAC GGT
ACT TAA ATT GTT TAC-3’); mef(A) 1, (5’-AGT
ATC ATT AAT CAC TAG TGC-3’); and mef(A) 2,
(5’-TTC TTC TGG TAC TAA AAG TGG-3’), which
were designed on the basis of previously published
sequences (18).
S. pneumoniae ATCC 49619, ATCC 700673, and
ATCC 51919 strains were used as negative, erm(B)positive, and mef(A)-positive controls, respectively.
The Pearson chi-square test was employed for
statistical analysis.

Results
Of the 300 pneumococcal isolates evaluated, 34
(11.4%) were found to be resistant to erythromycin,
azithromycin, and clarithromycin. For 23% of
isolates, the penicillin MIC value was 0.12-1 μg/mL,
whereas the MIC value was ≥2 μg/mL in only 2%
(Table 1). When the strains grouped and evaluated
as isolates from sterile fluids and respiratory tracts
were compared, it was found that the MIC90 values
of macrolide-group antibiotics in the strains isolated
from the respiratory tract samples (erythromycin and
azithromycin, 4 μg/mL; clarithromycin, 2 μg/mL) and
the macrolide resistance rates (11.4%) were higher
than those of the strains isolated from sterile fluids
(6.4%) (Table 1). However, these rate differences were
not statistically significant (P > 0.05). On the other
hand, when the strains with a penicillin MIC of ≤0.06
μg/mL were compared to those with a penicillin MIC
of ≥0.12 μg/mL, the macrolide resistance rate was
seen to increase from 4.5% to 32% (Tables 2 and 3).
The difference in macrolide resistance rates between
the strains susceptible to and resistant to penicillin
was noted to be statistically significant (P < 0.001).
Of the 300 strains, 34 (11.4%) were studied by the
E-test method and found to be macrolide resistant.
Genotypic evaluation of these strains demonstrated
that 20 (58.8%) were erm(B)-positive, 13 (38.2%)
were mef(A)-positive, and 1 (3%) was positive for
both erm(B) and mef(A).
When comparing mef(A)-positive strains with
erm(B)-positive strains, it was observed that the
number of strains with a penicillin MIC value
of ≥0.12 μg/mL in the group of erm(B)-positive
strains (n = 15) was much greater than the number
of mef(A)-positive strains (n = 8). Additionally, the
MIC50 and MIC90 values of penicillin were higher in
erm(B)-positive strains than mef(A)-positive strains.
While the MIC values of macrolide-group antibiotics
were determined to be at lower levels in mef(A)positive strains (n = 13), MIC values of macrolidegroup antibiotics were observed to be high in
erm(B)-positive strains (n = 20). In erm(B)-positive
strains, the rate of strains with a penicillin MIC of
≥0.12 μg/mL was 75%; it was 61.5% in the mef(A)positive strains (Tables 4 and 5). In both the erm(B)and mef(A)-positive strains, MIC values were 256 μg/
mL for macrolide and 2 μg/mL for penicillin.
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Table 1. The MIC50 and MIC90 values and resistance rates of macrolides and penicillin in S. pneumoniae strains isolated from clinical
samples.
Antibiotic

Susceptible

Intermediate

Resistant

n

n

n

(%)

0

34

(11.4)

266 (88.6)

0

34

(11.4)

2

266 (88.6)

0

34

(11.4)

0.023

0.75

224 (74.6)

70

6

(2.1)

Penicillin parenteral (non-menengitidis)

0.023

0.75

300 (100)

0

Penicillin oral

0.023

0.75

223 (74.3)

71

Erythromycin

0.023

4

140

(88.6)

0

18 (11.4)

Azithromycin

0.064

4

140

(88.6)

0

18 (11.4)

Clarithromycin

0.023

2

140

(88.6)

0

18 (11.4)

Penicillin (before 2008)

0.023

0.5

116

(73.4)

39

Penicillin parenteral (non-menengitidis)

0.023

0.5

158

(100)

0

Penicillin oral

0.023

0.5

114

(72.2)

41

Erythromycin

0.023

0.047

88

(93.6)

Azithromycin

0.047

0.25

88

Clarithromycin

0.016

0.047

Penicillin (before 2008)

0.023

Penicillin parenteral (menengitidis)
Penicillin parenteral (non-menengitidis)

MIC50
(μg/mL)

MIC90
(μg/mL)

Erythromycin

0.023

3

266 (88.6)

Azithromycin

0.064

3

Clarithromycin

0.023

Penicillin (before 2008)

All strains (n = 300)

(%)

(%)

(23.3)

0
(23.6)

6

(2.1)

Respiratory tract samples (n = 158)

(24.6)

3

(2)

0
(25.9)

3

(1.9)

0

6

(6.4)

(93.6)

0

6

(6.4)

88

(93.6)

0

6

(6.4)

0.5

70

(74.5)

23

1

(1)

0.023

0.5

72

(76.6)

0

22 (23.4)

0.023

0.5

94

(100)

0

0

Sterile fluids (n = 94)

(24.5)

Table 2. The MIC50 and MIC90 values and resistance rates in S. pneumoniae strains in which penicillin
MIC values were ≤0.06 μg/mL.

Antibiotic
(n = 224)

140

MIC50
(μg/mL)

MIC90 Susceptible
(μg/mL) n
(%)

Intermediate

Resistant

n

n

(%)

(%)

Erythromycin

0.023

0.047

214 (95.5)

10

(4.5)

Azithromycin

0.064

0.19

214 (95.5)

10

(4.5)

Clarithromycin

0.032

0.047

214 (95.5)

10

(4.5)
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Table 3. MIC50 and MIC90 values and resistance rates in S. pneumoniae strains in which penicillin MIC
values were ≥0.12 μg/mL.

Antibiotic
(n = 76)

Susceptible

Intermediate

Resistant

n

(%)

n

n

(%)

256

52

(68)

24

(32)

0.094

256

52

(68)

24

(32)

0.032

256

52

(68)

24

(32)

MIC50
(μg/mL)

MIC90
(μg/mL)

Erythromycin

0.032

Azithromycin
Clarithromycin

(%)

Table 4. MIC50 and MIC90 values and resistance rates of antibiotics in S. pneumoniae strains in which erm(B) genotypes were determined.
Susceptible

Intermediate

Resistant

n

n

n

(%)

256

20

(100)

256

256

20

(100)

64-256

256

256

20

(100)

Penicillin (before 2008)

0.012-2

0.5

1.5

5

(25)

13

2

(10)

Penicillin parenteral (non-menengitidis)

0.012-2

0.5

1.5

20

100)

0

Penicillin oral

0.012-2

0.5

1.5

5

(25)

13

Antibiotic
(n = 20)

MIC range
(μg/mL)

MIC50
(μg/mL)

MIC90
(μg/mL)

Erythromycin

96-256

256

Azithromycin

192-256

Clarithromycin

(%)

(%)

(65)

0
(65)

2

(10)

Table 5. MIC ranges, MIC50 and MIC90 values, and resistance rates of antibiotics in S. pneumoniae strains in which mef(A) genotypes
were determined.
MIC range
(μg/mL)

MIC50
(μg/mL)

Erythromycin

2-256

4

Azithromycin

3-256

Clarithromycin

MIC90 Susceptible
(μg/mL)
n
(%)

Intermediate

Resistant

n

n

(%)

24

13

(100)

4

24

13

(100)

2-256

3

12

13

(100)

Penicillin (before 2008)

0.008-2

1

2

5

(38.5)

6

2

(15.5)

Penicillin parenteral (non-menengitidis)

0.008-2

1

2

13

(100)

0

Penicillin oral

0.008-2

1

2

5

(38.5)

6

Antibiotic
(n = 13)

(%)

(46)

0
(46)

2

(15.5)
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Discussion
The rate of macrolide resistance in S. pneumoniae
ranges from 4% to 70% in worldwide surveillance
studies (5). In a study titled “Prospective Resistant
Organism Tracking and Epidemiology for the
Ketolide Telithromycin” (PROTEKT), of 3362
pneumococcal isolates collected from 69 centers in
25 countries, including Turkey, macrolide resistance
was determined at rates of 57.6%, 42.9%, and 28.6% in
the western European countries of France, Italy, and
Spain, respectively. Slightly lower rates of resistance
were determined in Germany (15.7%), England
(13.2%), and Sweden (4.7%). In the same study, the
macrolide resistance rate of the pneumococcal strains
from Turkey was 15.6% (10).
In our study, macrolide resistance (11.4%) was
determined to be at a lower level than rates in the
United States (30.9%), the Far East (71.4%-87.6%),
and European countries such as France (57.6%), Italy
(42.9%), and Spain (28.6%); it was higher, however,
than the levels in Sweden (4.7%) and the Netherlands
(7.8%). In many countries worldwide, macrolide and
penicillin resistance rates are similar. For example,
in the PROTEKT study conducted in the United
States from 2000 to 2001, macrolide resistance was
13.4%, 20.8%, and 65.8% in S. pneumoniae strains
with a penicillin MIC of ≤0.06 μg/mL, 0.12-1 μg/
mL, and ≥2 μg/mL, respectively (19). Similarly, in
the Alexander Project conducted from 1998 to 2000,
macrolide resistance rates in strains with a penicillin
MIC of ≤0.06 μg/mL, 0.12-1 μg/mL, and ≥2 μg/
mL were determined to be 9.9%, 41.8%, and 66.8%,
respectively (20). In our study, the rate of macrolide
resistance was 4.5% (n = 10) in the strains with a
penicillin MIC of ≤0.06 μg/mL, 27.1% (n = 19) in
strains with a penicillin MIC of 0.12-1 μg/mL, and
83.4% (n = 5) in strains with a penicillin MIC of ≥2
μg/mL. In a study conducted by Özalp et al. in Turkey,
the erythromycin resistance rate in S. pneumoniae
was 5%, whereas the rates of intermediate and high
levels of resistance to penicillin were 29.6% and 2%,
respectively (12). A previous study from Turkey
reported that, of 283 S. pneumoniae isolates, only
6 (2.1%) were resistant to azithromycin (11). In
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our study, the rate of erythromycin resistance in
pneumococcal strains was 11.4%, whereas resistance
rates with penicillin MIC values of 0.12-1 μg/mL and
≥2 μg/mL were 23% and 2%, respectively. Several
studies from different regions of Turkey reported that
the erythromycin resistance rate was between 13.6%
and 26.4% (21-23).
Among isolates of S. pneumonia, 2 principal
mechanisms of erythromycin resistance are known
to exist: a ribosomal methylase encoded by erm(B)
and an efflux pump encoded by mef(A) (6,7). In all
genotypic analysis studies, the erm(B) genotype was
determined to be widespread in the Far East and in
European countries such as Italy and Spain, where
macrolide resistance is higher; the mef(A) genotype
was widespread in North America (4). Likewise, the
rate of erm(B) genotype-positive strains was higher
in our study. The PROTEKT study conducted from
1999 to 2000 in 25 countries, including Turkey,
reported the genotypic distribution results of 1043
macrolide-resistant S. pneumoniae isolates as follows:
56.2%, erm(B); 35.3%, mef(A); 6.8% for both mef(A)
and erm(B); 0.2%, erm(A) subclass erm(TR); and
1.5% negative for all mechanisms tested (9). The
same study noted that the mechanisms of macrolide
resistance showed geographical variability, and
the mef(A) genotype prevailed in countries such
as Sweden, Germany, Hong Kong, and the United
States; the erm(B) genotype prevailed in other
European countries, Turkey, and in the Far East in
countries such as South Korea and Japan. It was also
reported that erm(B) and mef(A) genotypes coexist
at a high rate (38.3%) in South Korea. In our study,
it was observed that the rates of erm(B), mef(A), and
both genotypes together were 58.8%, 38.2%, and
3%, respectively. Similarly, previous studies reported
from Turkey demonstrated that the genotype leading
to macrolide resistance is usually erm(B) (21-23).
In conclusion, in an era in which treatment
protocols are prepared according to profiles of
resistance, macrolide resistance rates have been
gradually increasing. Based on the data from our
study, it may be suggested that, in Turkey, macrolide
resistance and erm(B) genotype rates are not higher
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than those in other countries. Including macrolidegroup antibiotics in treatment protocols should
be suitable because of the lower resistance rate. In
Turkey, data collected and obtained from multicenter
studies are needed for follow-up about resistance
to penicillin, macrolides, and other antibiotics in S.
pneumoniae strains, using suitable methods.
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